Evidence map›Paper›PMID 37782371›Full record

ArticleAnnals of hematology2024

Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.

Nicola Sgherza, Paola Curci, Rita Rizzi, Olga Battisti, Alberto Perfetto, Stefania Weigl, Angela M V Larocca, Maria Chironna, Silvio Tafuri, Pellegrino Musto

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nicola SgherzaHematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy. nicolasgherza@libero.it.ORCID http://orcid.org/0000-0001-5447-1068
Paola CurciHematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy.
Rita RizziHematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy.
Olga BattistiDepartment of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
Alberto PerfettoDepartment of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
Stefania WeiglHematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy.
Angela M V LaroccaHygiene Unit, AOUC Policlinico, Bari, Italy.
Maria ChironnaDepartment of Biomedical Sciences and Human Oncology, "Aldo Moro" University School of Medicine, Bari, Italy.
Silvio TafuriDepartment of Biomedical Sciences and Human Oncology, "Aldo Moro" University School of Medicine, Bari, Italy.
Pellegrino MustoHematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy. pellegrino.musto@uniba.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Multiple MyelomaCOVID-19 VaccinesHumansCOVID-19 VaccinesBreakthrough COVID-19Multiple myelomaVaccines against SARS-CoV-2

Identifiers

PMID37782371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.